Read more

July 19, 2024
3 min read
Save

Osteoporosis treatment equally lowers hip fracture risk for both men and women

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Older men have a similar reduction in hip fracture risk with osteoporosis treatment as women.
  • Researchers said the study provides strong evidence supporting the use of osteoporosis drugs for men.

Osteoporosis treatment reduces the risk for hip fractures for older men just as well as it does for older women, according to a study published in Journal of Bone and Mineral Research.

Eric Orwoll

“There is abundant evidence that men are not adequately screened for osteoporosis, and those with osteoporosis are frequently untreated,” Eric Orwoll, MD, professor of medicine at Oregon Health & Science University, told Healio. “A major reason for this is the perception that the effectiveness of treatments is not sufficiently documented in men. Some official guidelines do not recommend screening and treatment for osteoporosis in men because of this perception. The results of our study provide strong evidence that treatment is indeed effective to reduce fracture risk in men. We hope that this will change current practice approaches to improve the prevention of osteoporotic fractures in men.”

Osteoporosis hip Adobe
Osteoporosis treatment lowers the risk for hip fractures for men as well as women. Image: Adobe Stock

Assessing hip fracture risk

Orwoll and colleagues conducted a case-control observational study assessing electronic health data from Kaiser Permanente Southern California health care system. Adults aged 65 years or older who had an abdominal or pelvic CT scan performed from Jan. 1, 2005, to July 1, 2018, and did not have a hip fracture prior to their CT scan were eligible for inclusion in the study. Researchers identified 2,413 women and 792 men at high risk for a hip fracture, which was defined as a femoral neck or total hip bone mineral density T-score of –2.5 or lower. Tony M. Keaveny, PhD, distinguished professor in the departments of mechanical engineering and bioengineering at University of California, Berkeley, discussed how fracture risk was assessed in the study.

Tony M. Keaveny

“The key innovations were mining extensive medical record data from the Kaiser Permanente Southern California health care system and utilizing biomechanical computed tomography technology to re-purpose CT scans taken for past clinical care, to perform an accurate assessment of osteoporosis and fracture risk for each patient,” Keaveny told Healio.

Adults who had at least 180 days of osteoporosis medication prescription fills in the year following their CT scan were defined as receiving treatment, those who had prescription fills for 1 to 179 days received partial treatment and adults with no prescription fills were considered to have not received osteoporosis treatment.

Osteoporosis therapy benefits men

At 2 years, hip fractures occurred in 29.9% of women and 34% of men. Of adults who remained in the study for 2 years of follow-up, 33.9% of women and 24% of men were treated for osteoporosis, and 51.5% of women and 66.3% of men received no treatment. Alendronate prescriptions were filled by 80.4% of women and 89.7% of men, the researchers reported.

In adjusted logistic regression analyses, both women (adjusted OR = 0.26; 95% CI, 0.21-0.33) and men (aOR = 0.21; 95% CI, 0.13-0.34) receiving osteoporosis treatment were less likely to sustain a hip fracture than those receiving no treatment. There was no significant difference in the ORs for hip fractures between men and women, according to the study. There were also no differences for hip fractures odds between men and women in secondary analyses restricted to adults using alendronate, those aged 70 years and older, when the follow-up period was extended to 5 years and when adults who were lost to follow-up were added as no fracture controls.

Keaveny said he hopes that the findings will lead to changes in coverage of osteoporosis treatment for older men.

“Because of the lack of supporting clinical data, Medicare and private insurers do not typically cover osteoporosis testing for older men unless there are very specific risk factors, which most men don’t have,” Keaveny said. “As a result, although one in about every three hip fractures occurs in men, very few older men get tested for osteoporosis and fracture prevention for men is suboptimal. Our results will hopefully enable the relevant stakeholders to adjust guidelines and recommendations for how osteoporosis will be managed in men.”

For more information:

Tony M. Keaveny, PhD, can be reached at tonykeaveny@berkeley.edu.

Eric Orwoll, MD, can be reached at orwoll@ohsu.edu.